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Bullous Pemphigoid: Simple Measures
for a Complex Disease
Luigi Naldi1,2, Simone Cazzaniga1 and Luca Borradori3
Simple descriptive population data are potentially helpful in understanding how
bullous pemphigoid (BP) originates and evolves over time. Before embarking with
etiological correlations, artifacts and biases should be ruled out. Ideally, epide-
miological data should be complemented by immunological and genetic analyses
aimed at providing better insight into the causation and prognosis of BP.
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Bullous pemphigoid (BP) is the most
frequently occurring autoimmune sube-
pidermal blistering disease of the skin. It
typically affects the elderly population,
and it is characterized by an autoimmune
response specifically directed against
two target antigens: the BP antigen 180
(BP180, BPAG2 or type XVII collagen)
and the BP antigen 230 (BP230, also
called BPAG1-e). These proteins (anti-
gens) are components of junctional adhe-
sion complexes called hemidesmsomes,
promoting firm dermo-epidermal cohe-
sion. Recent studies have demonstrated
convincingly the pathogenic effects of
patients’ autoantibodies, and have further
dissected the mechanisms leading to
tissue damage and subepidermal blister
formation, such as complement activa-
tion, recruitment of inflammatory cells,
and release of inflammatory mediators
and proteases (Di Zenzo et al., 2012).
In this issue, Joly et al. (this issue)
demonstrate how simple descriptive
population data can be helpful in under-
standing the way BP originates and
evolves over time, and illustrate how
epidemiological analysis of a disease
may stimulate both clinical and bench
research.
Incidence and mortality
Incidence is a measure of the risk (or
probability) of developing a condition
within a specified period of time. The
choice of the appropriate denominator
is a crucial step in descriptive epidemio-
logy (Figure 1). Incidence studies usually
exclude from the numerator individuals
who are already affected at the beginning
of the study, and others who are not at
risk for the disease (e.g., women who
have had hysterectomies in a study of
endometrial cancer). Two incidence mea-
sures can be calculated according to the
denominator selected (Victora, 1993).
A first choice of denominator is the
initial population at risk. If they are
followed up until a given time point,
the number of new incident cases
divided by the initial population gives
the incidence risk, also known as cumu-
lative incidence. When patients are lost
to follow-up, methods to account for
such losses can be adopted, such as the
Kaplan–Meier technique or parametric
estimation of cumulative incidence
functions. An incidence risk is a propor-
tion with values ranging from 0 to 1 or,
expressed as a percentage, from 0 to
100%. For example, in the study by Joly
et al., the risk of dying during the first
year after the diagnosis of BP has been
made was 38% (and hence, the survival
rate was 62%). These estimates were
obtained by relying on a Kaplan–Meier
approach. The ratio of the number of
deaths observed in the study group to
the number that would be expected if
the study population had the same
specific rates as a standard reference
population is the standardized mortality
ratio. In the study by Joly et al., the
standardized mortality ratio of patients
with BP was 6.6, meaning that the risk
of death in this group of patients was
more than six times greater than that of
the general population. At variance with
what Joly et al. seem to imply, this does
not translate automatically that the risk
of death is attributable to BP. It could be
explained by comorbidities, treatment
for the disease, or other confounders.
Although the increased risk of death
could be related to other confounders,
we have recently found that the stan-
dardized mortality ratio is particularly
high in people below the age of 70
years, an observation suggesting that
mortality can be directly attributed to
BP or its treatment, rather than to other
causes, as it might be in an older age
group (Corte´s et al., 2011).
When the number of people at risk
changes over time, an incidence rate
(also called incidence density or force
of morbidity), rather than cumulative
incidence, can be calculated. The
denominator is expressed as person-
time units. Each person who is followed
up for one time unit (for example, a
month or a year) represents one person-
time. In calculating rates for a geogra-
phical area where the exact number of
person-time is not known, the mid-time
population provides a reasonable esti-
mate. For example, in the study by Joly
et al., incident (i.e., newly diagnosed)
cases of BP were identified from January
2000 to December 2005 in three
French regions. The denominator was
represented by the mid-period (year
2003) populations in the regions,
amounting to 3.858 million inhabitants,
and the overall incidence rate of BP was
21.7 cases per million-persons per year,
about three-fold higher than the inci-
dence estimated 15 years earlier. An
incidence rate is a ratio ranging from 0
to þN, because the numerator is not
contained in the denominator (person-
time). By incorporating person-time,
incidence rate reflects the velocity of
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the spread of a disease in a given popu-
lation. If a disease is rare and if deaths
and losses to follow-up are limited, the
incidence risk and rate will be similar,
provided that they are expressed in the
same time units. As in the report by Joly
et al., incidence risks are usually more
appropriate for presenting the prog-
nosis of individual patients, whereas
incidence rates are more appropriate
for ecological correlations and etiologi-
cal research.
Pitfalls when interpreting data
Comparisons of incidence data over
time and between different groups offer
a first and simple means to assess the
impact of potential etiological factors.
For example, changes in the expo-
sure to provocative factors may be an
explanation for the threefold increase in
incidence of BP observed by Joly and
colleagues (2011) over 15 years. Before
embarking with etiological correlations,
artifacts and biases should be ruled out.
When modeling incidence data, three
components should be thoroughly exam-
ined, which are usually referred to as
age, period, and cohort effects. Age
effects are the consequences of growing
older. We all know that the incidence of
BP increases with age. Period effects are
the consequences of influences that vary
through time, for example, improvement
in diagnostic procedures, which may
influence the identification of new cases.
Cohort effects are the consequences of
being born at different times. These influ-
ences are intermingled and difficult to
separate. Age effects could be controlled
for by referring to standardized rates, or by
calculating and comparing age-specific
rates. It is unclear whether Joly et al.,
determined direct standardization of inci-
dence rates, using a reference standard
population such as the European Standard
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Figure 1. Measures of incidence in a population: total population at baseline is represented by both
diseased subjects and disease-free subjects (a0þ n0). Cumulative incidence at different time points is
calculated as the ratio of subjects developing disease after t0 and disease-free population at t0 (e.g., I2¼ d2/
n0). In the incidence-density definition, instead, the denominator is computed as the total person-time
units at some time point after t0, and it is represented in the figure by the white area. (Adapted from
Victora, 1993.)
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Figure 2. Schematic representation of the protein structure of the three major isoforms of human BPAG1-e (BP230), BPAG1-a, and BPAG1-b. BPAG1-e, -a
(isoform 1), and -b (isoform 1) are 2649, 5457, and 7543 residues long, respectively (accession number NP_001714, CAI14342, and CAI14341, respectively).
There are three isoforms for both BPAG1-a and -b, which differ in their NH2 terminus (not depicted). All BPAG1 isoforms contain the same plakin domain, consisting
of spectrin repeats (SR; oval) and an src homology domain 3 (SH3), embedded in the fifth SR. Depending on the isoform, several additional domains can be
found: in BPAG1-e, a rod domain, composed of two coiled coils (CC, rectangles) responsible for homo-dimerization of BPAG-1e, an IF-binding domain (IFBD)
consisting of two plakin repeat domains (PRD, rectangles), each formed by several plectin repeats (not shown). BPAG1-a and -b (isoform 1) contain an actin-binding
domain (ABD), formed by two calponin homology domains (black bars), numerous SRs outside the plakin domain (oval), a calcium-binding domain (Ca) consisting
of 2EF hands (black lines) and a microtubule-binding domain (MTBD, black hexagon) with high similarity to the GAS2/GAR domain. BPAG1-b specifically bears
after the plakin domain 2 PRDs (rectangles), termed PRD2. The starting residue for each domain is indicated at the top. The region of homology with perfect identity of
the amino acid sequence between the epidermal and neuronal BPAG1 isoforms thus only encompasses the plakin domain in their NH2 terminal portion.
COMMENTARY
www.jidonline.org 1949
Population, before comparing rates bet-
ween different time periods. If that was the
case, then aging of the population could
not explain the variations in incidence
observed over time. Improved detection
may partly explain the increased inci-
dence that Joly et al. observed in the
more recent years of their study. In fact,
about 21% of the patients in the study had
atypical clinical features of BP, some of
which were described only recently.
Several independent studies have
demonstrated an association between
BP and neurological disorders (Taghi-
pour et al., 2010; Bastuji-Garin et al.,
2011; Langan et al., 2011). A significant
association was shown with Parkinson’s
disease, dementia, psychiatric disorders
(unipolar and bipolar disorders), and
stroke. In a population-based study, a
strong association was documented
with multiple sclerosis (Langan et al.,
2011). Notably, the development of
specific neurological diseases preceded
the onset of BP (Taghipour et al., 2010;
Langan et al., 2011). The relation-
ship between neurological disorders
and BP could partly explain both the
increase in incidence of BP observed in
more recent years and the increased
mortality in BP patients as compared
with the general population.
The intriguing link with neurological
disorders
Besides BP230 (BPAG1-e), the epidermal
variant, the dystonin gene encodes differ-
ent isoforms exhibiting a tissue-specific
expression profile, such as the neuronal
specific isoform, BPAG1-a, and the
muscle-specfic isoform, BPAG1-b (Leung
et al., 2001) (Figure 2). BPAG1-a is a
protein of 625 kDa, abundantly expressed
in pituitary primordial and the dorsal root
ganglia. It differs from BPAG1-e by the
presence of an actin-binding domain
at the NH2 terminus of the protein and
a second spectrin domain downstream
of the plakin domain, followed by a
microtubule-binding domain at the
COOH terminus instead of the coiled-
coil domain and intermediate filament-
binding domain found in BPAG1-e. On
the basis of the fact that these proteins
share an approximate 1,000 amino acid
residue stretch in the N-terminal region,
it has been suggested that break of tole-
rance induced by neuronal degeneration
may lead to an immune response to
BPAG1-a, with subsequent cross-react-
ivity to BP230/BPAG1-e and intermole-
cular ‘‘epitope spreading,’’ which may
contribute to the development of BP in
association with neurological disorders
such as Parkinson’s disease, Alzheimer’s
disease, or multiple sclerosis (Laffitte
et al., 2005). This hypothesis is contras-
ted by the observation that BPAG1-a
is poorly or not at all expressed in the
central nervous tissue sites relevant to
the neurological diseases reported in
association with BP. It has also been
documented that patients with BP have
elevated serum levels of pro-inflammatory
cytokines, soluble E-selectin, and vascular
endothelial growth factor, indicating
endothelial activation (Di Zenzo et al.,
2012). The activation of luminal endothe-
lium in BP could predispose patients to
various vascular events, including stroke
(Yang et al., 2011).
Combining data in molecular and
genetic epidemiology
The recent epidemiological studies and
clinical trials of BP carried out by the
French Group for Bullous Diseases should
be complemented by further immunolo-
gical and genetic studies aimed at provid-
ing better insight into the development of
the immune response in BP patients
beyond mouse models. Ongoing prospec-
tive European multicenter studies of the
immunological profile of BP patients and
its dynamics during the clinical course of
the disease have begun to demonstrate
intramolecular and intermolecular epi-
tope spreading events in vivo (Di Zenzo
et al., 2011). Genome-wide association
studies in large patient cohorts are expec-
ted to reveal associations of BP with
genes encoding novel proteins relevant
to disease development. Hence, despite
the significant advances in our understand-
ing of BP over the past decade, the best
is surely yet to come. Considering the
growing number of BP patients and the
related healthcare burden, the establish-
ment of management guidelines to
ensure optimal patient care is another
important goal to bear in mind.
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